SphingoTec to Present at the Solebury Trout’s Summer Private Company Showcase

Hennigsdorf/Berlin, Germany – August 6, 2020 – Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand Von Humboldt, CFO, will be presenting a corporate overview at the Summer Private Company Showcase, hosted by Solebury Trout on August 10, 2020.

SphingoTec develops and markets in-vitro diagnostic tests for novel and proprietary biomarkers in diagnostically underserved acute and critical care conditions to improve patient outcomes. The company makes its assays for real-time assessment of kidney function, endothelial function and cardiac depression available on its fully integrated Nexus IB10 point-of-care platform.

Presentation Details:
Date: August 10, 2020
Time: 4:00 p.m. CEST

Please click the following link to register:

About SphingoTec
SphingoTec GmbH ( “SphingoTec”; Hennigsdorf near Berlin, Germany) develops and markets innovative in-vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin(bio-ADM®), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid®), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression. IVD tests for SphingoTec’s proprietary biomarkers are made available as sphingotest® microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec’s subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.

SphingoTec GmbH
Ferdinand von Humboldt
+ 49 330 220 56 50

No Comments Yet.

Leave a comment